54216 Investors following Ranbaxy Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Stay away from Ranbaxy: Baliga
Ambareesh Baliga of Karvy Stock Broking is of the opinion that one should stay away Ranbaxy Laboratories because it is going more towards the levels of Rs 400, so closer to Rs 400 or Rs 410, it makes sense in investing in this company for slightly longer term perspective.
Baliga told CNBC-TV18, "For the time being I would say stay away from Ranbaxy because we see it going more towards the levels of Rs 400, so closer to Rs 400 or Rs 410, it makes sense in investing in this company for slightly longer term perspective. For the time being one should ignore it because clearly post this open offer, the price should go down to levels of Rs 400 to Rs 410."
Disclosure: It is safe to assume that analyst and his client may have an investment interest in the above stock/sector.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Tata Motors | Uninor | Aurobindo Pharma | Naveen Patnaik | Suzlon Energy | Tamil Nadu | Securities and Exchange Board of India | Bonus share | Consumer Confidence Index | Lucas Papademos 
